Corvidia

Corvidia is a clinical-stage biotechnology company dedicated to leveraging functional genomics research to analyze genetic variations carried by patients with cardiovascular and kidney diseases and to develop personalized precision therapies targeting these genetic variations. The company's candidate drug COR-001 is nearing the completion of Phase 2 clinical trials for the treatment of genetically defined advanced chronic kidney disease patients. Another candidate product, COR-003, is also about to enter clinical trials for the treatment of patients with hypertriglyceridemia. In addition, Corvidia has a series of innovative candidate therapies targeting kidney and cardiovascular diseases.